November 1, 2008Therapy
The search for new anticoagulants: dabigatran etexilate
Key result
Dabigatran offers predictable anticoagulation without routine monitoring for VTE prevention after hip and knee replacement.
Design
Review
Authors
Discussion
Loading...
Member takes
Implication
Dabigatran offers a convenient monitoring-free option for post-orthopedic VTE prophylaxis; leaves open comparative effectiveness and long-term safety versus other agents.
Structured PICO
I
Intervention
Dabigatran etexilate
Dabigatran etexilate is an oral direct thrombin inhibitor that provides predictable anticoagulation without monitoring, offering a convenient alternative to traditional anticoagulants for VTE prevention.
Limitations
- Further observations of long-term dabigatran safety are required.
- Further observations of long-term dabigatran safety are required regarding potential hepatotoxicity
Cite This Study
Shantsila et al. (2008) conducted a review in Thromboembolism-related disorders. Dabigatran etexilate vs. Traditional anticoagulants was evaluated. Dabigatran etexilate is an oral direct thrombin inhibitor offering predictable anticoagulation without routine monitoring, approved in the EU for VTE prevention following hip and knee replacement.